Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10470685 | 0.96 | CNR1 (0.50) | CNR1IKBKBTSHRPGRAPP | |
| SCHEMBL9927249 | 0.88 | APP (0.48) | CNR1PGRAPPRAB9AKDM4E | |
| SCHEMBL13424304 | 0.85 | APP (0.46) | CNR1PGRAPPPOLBRAB9A | |
| SCHEMBL10300218 | 0.85 | APP (0.46) | CNR1PGRAPPPOLBRAB9A | |
| SCHEMBL13376691 | 0.83 | APP (0.50) | PGRAPPNPC1ALDH1A1MAPT | |
| SCHEMBL18188060 | 0.83 | IKBKB (0.57) | CNR1IKBKBAPPPOLBKDM4E | |
| SCHEMBL147842 | 0.81 | HSD17B1 (0.44) | PGRAPPTDP1POLBKDM4E | |
| SCHEMBL14363103 | 0.80 | CNR1 (0.44) | CNR1TSHRPGRPOLBRAB9A | |
| SCHEMBL147152 | 0.79 | CNR1 (0.55) | CNR1POLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12307014 | 0.79 | APP (0.46) | PGRAPPKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180189-B2 | Proteostasis regulators | Kineta, Inc. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3756667-B1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIV OSLO (NO) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | Kineta, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2020-08-18 | — | — | US | disclosed |
| EP-3552664-A1 | PROTEOSTASIS REGULATORS | Proteostasis Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20110210318-A1 | MATERIAL FOR ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2011-09-01 | — | — | US | disclosed |
| US-20110210318-A1 | MATERIAL FOR ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2011-09-01 | — | — | US | disclosed |
| EP-2332911-A2 | MATERIAL FOR ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG Chem, Ltd. (KR) | 2011-06-15 | — | — | EP | disclosed |
| EP-1694410-B1 | CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-1768985-B1 | PYRIMIDO-BENZIMIDAZOLE DERIVATIVES AND THE USE THEREOF IN THE FORM OF AGONISTS OR ANTAGONISTS OF MELANOCORTIN RECEPTORS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | CNR1 3350/4885IKBKB 492/4885TSHR 4284/4885 |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | CNR1 4180/4885IKBKB 1829/4885TSHR 3397/4885 |
| US-20110210318-A1 | MATERIAL FOR ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE USING SAME | OR51E2, OR10J3, EML4 | CNR1 4710/4885IKBKB 4292/4885TSHR 4792/4885 |
| US-12180189-B2 | Proteostasis regulators | PSMG3, VCP, HSPA5 | CNR1 3350/4885IKBKB 492/4885TSHR 4284/4885 |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | CNR1 4180/4885IKBKB 1829/4885TSHR 3397/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CNR1 2323/4885IKBKB 1932/4885TSHR 2373/4885 |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | CNR1 3350/4885IKBKB 492/4885TSHR 4284/4885 |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | CNR1 4180/4885IKBKB 1829/4885TSHR 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.